GlassScriptPhysician profile
Hisham S Sadek
NPI 1619941614
$1,433.93
in general payments reported to CMS, 2019-2025
14 companies · $197 in 2025
The $197 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $13.20 · 2021: $121 · 2022: $290 · 2023: $379 · 2024: $434 · 2025: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,010.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,010.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $301.77 | 2022-2024 | Ingrezza |
| Janssen Pharmaceuticals, INC | $251.63 | 2021-2024 | Invega Sustenna, Invega Trinza, Spravato |
| Alkermes, INC. | $215.09 | 2023-2025 | Aristada, Aristada Initio, Lybalvi |
| Abbvie INC. | $140.92 | 2021-2023 | Vraylar |
| E.R. Squibb & Sons, L.L.C. | $132.48 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $98.84 | 2023-2024 | Uzedy |
| Lundbeck LLC | $98.47 | 2023-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Glaxosmithkline, LLC. | $43.93 | 2020-2021 | |
| Vanda Pharmaceuticals INC. | $43.42 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $41.54 | 2022-2023 | Abilify Maintena, Rexulti |
| Almatica Pharma LLC | $22.83 | 2021 | |
| Noven Therapeutics, LLC | $15.24 | 2025 | Xelstrym |
| Ucb, INC. | $14.96 | 2023 | Nayzilam |
| Abbott Laboratories | $12.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hisham Sadek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.